Interpace Diagnostics, a subsidiary of PFI, announced results from a study that found that PancraGen (previously known as PathFinderTG-Pancreas) is 90 percent accurate at predicting benign and malignant disease in patients with pancreatic cysts.
The results of the PancraGen multicenter clinical validation study will be published in the February issue of Endoscopy. The study included 492 patients who had PancraGen testing as part of their care when cytological analysis of cyst fluid was inconclusive.
"The results from this study indicate that PancraGen testing can help healthcare providers make the most appropriate management recommendations for their patients," said Mohammad Al-Haddad, MD, director of endoscopy at Cleveland Clinic Abu Dhabi.
More articles on GI/endoscopy:
New drugs, screening tactics could nearly eliminate HCV by 2036
Does physical health play a role in gastroenterologist burnout? 6 statistics
HCV outbreak confirmed at Tri-City Colonoscopy Clinic in Canada